Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart Failure | 54 | 2024 | 11837 | 2.810 |
Why?
|
Anthracyclines | 10 | 2023 | 285 | 2.260 |
Why?
|
Myocarditis | 13 | 2023 | 803 | 1.650 |
Why?
|
Neoplasms | 31 | 2024 | 22340 | 1.490 |
Why?
|
Cardiomyopathies | 8 | 2023 | 2068 | 1.180 |
Why?
|
Cardiovascular Agents | 5 | 2023 | 848 | 1.060 |
Why?
|
Adrenergic beta-Antagonists | 6 | 2019 | 1238 | 0.830 |
Why?
|
Antineoplastic Agents | 13 | 2024 | 13631 | 0.820 |
Why?
|
Cardiotonic Agents | 4 | 2015 | 539 | 0.810 |
Why?
|
Heart Neoplasms | 2 | 2023 | 374 | 0.800 |
Why?
|
Atherosclerosis | 5 | 2023 | 3419 | 0.780 |
Why?
|
Radiotherapy | 8 | 2021 | 1491 | 0.730 |
Why?
|
Mediastinal Neoplasms | 1 | 2023 | 403 | 0.710 |
Why?
|
Antibiotics, Antineoplastic | 6 | 2023 | 678 | 0.680 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2023 | 3249 | 0.630 |
Why?
|
Diuretics | 8 | 2015 | 611 | 0.620 |
Why?
|
Renal Insufficiency | 4 | 2022 | 810 | 0.620 |
Why?
|
Acute Coronary Syndrome | 2 | 2022 | 2185 | 0.600 |
Why?
|
Breast Neoplasms | 10 | 2024 | 21069 | 0.590 |
Why?
|
Heart | 8 | 2023 | 4419 | 0.570 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2019 | 645 | 0.500 |
Why?
|
Heart Diseases | 7 | 2022 | 2818 | 0.480 |
Why?
|
Heart Rate | 4 | 2023 | 4203 | 0.480 |
Why?
|
Heart-Assist Devices | 3 | 2023 | 1297 | 0.470 |
Why?
|
Fluorouracil | 1 | 2019 | 1648 | 0.460 |
Why?
|
Cardiac Resynchronization Therapy Devices | 1 | 2015 | 122 | 0.450 |
Why?
|
Echocardiography | 6 | 2020 | 5040 | 0.440 |
Why?
|
Heart Transplantation | 9 | 2023 | 3310 | 0.430 |
Why?
|
Salicylates | 1 | 2014 | 125 | 0.430 |
Why?
|
Dyspnea | 5 | 2019 | 1351 | 0.430 |
Why?
|
Humans | 131 | 2024 | 765926 | 0.430 |
Why?
|
Vasodilator Agents | 4 | 2014 | 988 | 0.420 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2020 | 1374 | 0.420 |
Why?
|
Vasodilation | 3 | 2014 | 969 | 0.420 |
Why?
|
Hemodynamics | 9 | 2012 | 4186 | 0.420 |
Why?
|
Cardiovascular Diseases | 12 | 2024 | 15645 | 0.420 |
Why?
|
Radiation Injuries | 6 | 2019 | 1181 | 0.410 |
Why?
|
Natriuretic Peptide, Brain | 6 | 2024 | 1735 | 0.410 |
Why?
|
Cardiomyopathy, Restrictive | 1 | 2012 | 61 | 0.400 |
Why?
|
rho-Associated Kinases | 3 | 2008 | 291 | 0.400 |
Why?
|
Saline Solution, Hypertonic | 2 | 2010 | 116 | 0.400 |
Why?
|
Stroke Volume | 14 | 2024 | 5595 | 0.390 |
Why?
|
Hodgkin Disease | 3 | 2021 | 1383 | 0.390 |
Why?
|
Hematologic Neoplasms | 1 | 2023 | 1926 | 0.380 |
Why?
|
Electrocardiography | 5 | 2021 | 6409 | 0.370 |
Why?
|
Catheterization, Swan-Ganz | 3 | 2012 | 87 | 0.370 |
Why?
|
Secondary Prevention | 1 | 2017 | 1470 | 0.370 |
Why?
|
Ventricular Function, Left | 10 | 2023 | 3930 | 0.360 |
Why?
|
Ventricular Dysfunction, Left | 6 | 2023 | 2136 | 0.360 |
Why?
|
Exercise Tolerance | 2 | 2018 | 841 | 0.360 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2021 | 1563 | 0.350 |
Why?
|
Endothelium, Vascular | 3 | 2014 | 4423 | 0.340 |
Why?
|
Autonomic Nervous System | 1 | 2015 | 706 | 0.330 |
Why?
|
Physical Examination | 2 | 2013 | 1263 | 0.330 |
Why?
|
Posture | 1 | 2013 | 955 | 0.330 |
Why?
|
Neovascularization, Pathologic | 1 | 2019 | 2627 | 0.320 |
Why?
|
Cardiac Resynchronization Therapy | 1 | 2015 | 562 | 0.320 |
Why?
|
Aortic Valve Stenosis | 1 | 2021 | 2022 | 0.300 |
Why?
|
Doxorubicin | 1 | 2015 | 2226 | 0.300 |
Why?
|
Pyrazoles | 1 | 2018 | 2031 | 0.290 |
Why?
|
Pyrimidines | 2 | 2018 | 3049 | 0.290 |
Why?
|
Risk Factors | 25 | 2024 | 74850 | 0.290 |
Why?
|
Female | 66 | 2024 | 396141 | 0.280 |
Why?
|
Exercise Test | 4 | 2020 | 2185 | 0.280 |
Why?
|
Stroke | 4 | 2024 | 9739 | 0.280 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 6 | 2022 | 5379 | 0.280 |
Why?
|
Coronary Artery Disease | 5 | 2024 | 6544 | 0.280 |
Why?
|
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2006 | 56 | 0.280 |
Why?
|
Fractional Flow Reserve, Myocardial | 2 | 2021 | 346 | 0.270 |
Why?
|
Atrial Fibrillation | 3 | 2023 | 5186 | 0.270 |
Why?
|
Caregivers | 1 | 2019 | 2304 | 0.270 |
Why?
|
Retrospective Studies | 31 | 2024 | 81537 | 0.270 |
Why?
|
Pulsatile Flow | 2 | 2012 | 318 | 0.260 |
Why?
|
Radiation Dosage | 7 | 2023 | 1945 | 0.260 |
Why?
|
Resuscitation | 1 | 2010 | 681 | 0.250 |
Why?
|
Aged | 43 | 2024 | 171163 | 0.250 |
Why?
|
Middle Aged | 52 | 2024 | 223016 | 0.250 |
Why?
|
Cardiomegaly | 1 | 2008 | 590 | 0.240 |
Why?
|
Myocardial Infarction | 3 | 2023 | 11508 | 0.240 |
Why?
|
Myocardial Perfusion Imaging | 2 | 2021 | 669 | 0.240 |
Why?
|
Kidney | 4 | 2022 | 7073 | 0.240 |
Why?
|
Male | 62 | 2024 | 363815 | 0.240 |
Why?
|
Thoracic Neoplasms | 2 | 2020 | 267 | 0.240 |
Why?
|
Blood Volume | 1 | 2006 | 544 | 0.230 |
Why?
|
Lung Neoplasms | 8 | 2022 | 13446 | 0.230 |
Why?
|
Coronary Vessels | 5 | 2022 | 3094 | 0.230 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 2270 | 0.220 |
Why?
|
Vascular Diseases | 3 | 2021 | 1161 | 0.220 |
Why?
|
Prognosis | 12 | 2021 | 29890 | 0.210 |
Why?
|
Colorectal Neoplasms | 2 | 2021 | 6958 | 0.210 |
Why?
|
Fingers | 1 | 2006 | 509 | 0.210 |
Why?
|
Acute Disease | 5 | 2022 | 7236 | 0.210 |
Why?
|
Topoisomerase II Inhibitors | 1 | 2022 | 94 | 0.200 |
Why?
|
Heart Atria | 1 | 2008 | 1363 | 0.190 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2023 | 125 | 0.190 |
Why?
|
Endothelin-1 | 1 | 2003 | 295 | 0.190 |
Why?
|
Patient Readmission | 2 | 2015 | 3282 | 0.190 |
Why?
|
Benzazepines | 1 | 2023 | 308 | 0.190 |
Why?
|
Lymphoma, T-Cell | 1 | 2023 | 308 | 0.180 |
Why?
|
Myasthenia Gravis | 1 | 2023 | 214 | 0.180 |
Why?
|
Giant Cells | 1 | 2021 | 187 | 0.180 |
Why?
|
Pulmonary Wedge Pressure | 3 | 2011 | 277 | 0.170 |
Why?
|
Diabetes Mellitus, Type 2 | 5 | 2024 | 12235 | 0.170 |
Why?
|
Myositis | 1 | 2023 | 271 | 0.170 |
Why?
|
Septal Occluder Device | 1 | 2021 | 126 | 0.170 |
Why?
|
Amyloid Neuropathies, Familial | 1 | 2023 | 187 | 0.160 |
Why?
|
Symporters | 1 | 2022 | 362 | 0.160 |
Why?
|
Registries | 5 | 2023 | 8346 | 0.160 |
Why?
|
Pericardial Effusion | 1 | 2021 | 245 | 0.160 |
Why?
|
Hyperlipidemias | 1 | 2024 | 770 | 0.160 |
Why?
|
Survival Rate | 6 | 2020 | 12822 | 0.160 |
Why?
|
Hypertension | 3 | 2024 | 8616 | 0.160 |
Why?
|
Autonomic Nervous System Diseases | 1 | 2021 | 269 | 0.150 |
Why?
|
Cause of Death | 4 | 2024 | 3715 | 0.150 |
Why?
|
Lymphocyte Count | 1 | 2020 | 791 | 0.150 |
Why?
|
Algorithms | 4 | 2021 | 14064 | 0.150 |
Why?
|
Glomerular Filtration Rate | 2 | 2022 | 2233 | 0.140 |
Why?
|
Treatment Outcome | 15 | 2023 | 65194 | 0.140 |
Why?
|
Cardiac Surgical Procedures | 3 | 2021 | 3682 | 0.140 |
Why?
|
Atrial Appendage | 1 | 2021 | 284 | 0.140 |
Why?
|
Cardiology Service, Hospital | 1 | 1999 | 242 | 0.140 |
Why?
|
Nitric Oxide | 1 | 2006 | 2141 | 0.140 |
Why?
|
Incidence | 8 | 2024 | 21513 | 0.140 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 4 | 2014 | 1513 | 0.140 |
Why?
|
Heptanoic Acids | 2 | 2008 | 344 | 0.140 |
Why?
|
Nutrition Surveys | 1 | 2024 | 1735 | 0.130 |
Why?
|
Carotid Stenosis | 1 | 2024 | 857 | 0.130 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2006 | 2879 | 0.130 |
Why?
|
Anticholesteremic Agents | 1 | 2023 | 970 | 0.130 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 1 | 2017 | 93 | 0.130 |
Why?
|
Hypercholesterolemia | 1 | 2003 | 1148 | 0.130 |
Why?
|
Patient Admission | 2 | 2022 | 1365 | 0.130 |
Why?
|
Cyclosporine | 1 | 1998 | 777 | 0.130 |
Why?
|
Hospice Care | 1 | 2022 | 678 | 0.130 |
Why?
|
Heart Valves | 1 | 2017 | 284 | 0.120 |
Why?
|
Heart Conduction System | 1 | 2021 | 1007 | 0.120 |
Why?
|
Aged, 80 and over | 11 | 2022 | 59496 | 0.120 |
Why?
|
Intracranial Hemorrhages | 1 | 2021 | 809 | 0.120 |
Why?
|
Antibodies | 1 | 2023 | 2415 | 0.120 |
Why?
|
Oxygen Consumption | 1 | 2021 | 1872 | 0.120 |
Why?
|
Delphi Technique | 1 | 2019 | 893 | 0.120 |
Why?
|
Hospitalization | 9 | 2024 | 10810 | 0.120 |
Why?
|
Cross-Over Studies | 2 | 2014 | 2108 | 0.110 |
Why?
|
Activities of Daily Living | 2 | 2022 | 2414 | 0.110 |
Why?
|
Ambulatory Care | 4 | 2016 | 2778 | 0.110 |
Why?
|
Disease Management | 4 | 2021 | 2530 | 0.110 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2008 | 2307 | 0.110 |
Why?
|
Adult | 20 | 2024 | 223088 | 0.110 |
Why?
|
Body Water | 1 | 2015 | 337 | 0.110 |
Why?
|
Follow-Up Studies | 10 | 2021 | 39228 | 0.110 |
Why?
|
Action Potentials | 1 | 2021 | 1837 | 0.110 |
Why?
|
Regional Blood Flow | 3 | 2008 | 1479 | 0.110 |
Why?
|
Myocardial Ischemia | 1 | 2024 | 2132 | 0.110 |
Why?
|
Defibrillators, Implantable | 3 | 2021 | 1497 | 0.110 |
Why?
|
Overweight | 1 | 2024 | 2444 | 0.100 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2022 | 2769 | 0.100 |
Why?
|
Death, Sudden | 2 | 2019 | 301 | 0.100 |
Why?
|
Giardia lamblia | 1 | 1992 | 23 | 0.100 |
Why?
|
Comorbidity | 6 | 2019 | 10575 | 0.100 |
Why?
|
Adenine | 1 | 2018 | 994 | 0.100 |
Why?
|
Vascular Endothelial Growth Factor C | 1 | 2013 | 124 | 0.100 |
Why?
|
Pyrroles | 2 | 2008 | 1119 | 0.100 |
Why?
|
Genes, Protozoan | 1 | 1992 | 170 | 0.100 |
Why?
|
Protein Kinase Inhibitors | 2 | 2020 | 5691 | 0.100 |
Why?
|
Health Services Needs and Demand | 1 | 2020 | 1404 | 0.100 |
Why?
|
Weight Loss | 2 | 2022 | 2710 | 0.100 |
Why?
|
Lymphoma, B-Cell | 1 | 2018 | 943 | 0.100 |
Why?
|
Peptide Fragments | 1 | 2024 | 5126 | 0.090 |
Why?
|
Survivors | 3 | 2023 | 2373 | 0.090 |
Why?
|
Creatinine | 4 | 2008 | 1916 | 0.090 |
Why?
|
Influenza Vaccines | 1 | 2019 | 780 | 0.090 |
Why?
|
Arrhythmias, Cardiac | 1 | 2021 | 2255 | 0.090 |
Why?
|
Cross Infection | 1 | 2020 | 1426 | 0.090 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1881 | 0.090 |
Why?
|
Sodium, Dietary | 1 | 2015 | 426 | 0.090 |
Why?
|
Immunity, Cellular | 1 | 2017 | 1555 | 0.090 |
Why?
|
Angiogenesis Inducing Agents | 1 | 2013 | 254 | 0.090 |
Why?
|
Fatigue | 3 | 2016 | 1553 | 0.090 |
Why?
|
Severity of Illness Index | 6 | 2021 | 15878 | 0.090 |
Why?
|
Aortic Valve | 1 | 2021 | 1964 | 0.090 |
Why?
|
Edema | 2 | 2012 | 759 | 0.090 |
Why?
|
Predictive Value of Tests | 7 | 2022 | 15401 | 0.090 |
Why?
|
Terminal Care | 1 | 2022 | 1769 | 0.090 |
Why?
|
Case-Control Studies | 4 | 2023 | 22228 | 0.080 |
Why?
|
Catheter Ablation | 1 | 2023 | 2787 | 0.080 |
Why?
|
Time Factors | 9 | 2021 | 40097 | 0.080 |
Why?
|
Piperidines | 1 | 2018 | 1664 | 0.080 |
Why?
|
Heart Valve Diseases | 1 | 2017 | 1029 | 0.080 |
Why?
|
Head and Neck Neoplasms | 1 | 2024 | 2924 | 0.080 |
Why?
|
Immunosuppressive Agents | 2 | 2021 | 4213 | 0.080 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 1 | 2010 | 156 | 0.080 |
Why?
|
Sodium | 3 | 2022 | 1591 | 0.080 |
Why?
|
Double-Blind Method | 3 | 2014 | 12417 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 1999 | 2782 | 0.080 |
Why?
|
Brachial Artery | 2 | 2008 | 374 | 0.080 |
Why?
|
Adjuvants, Immunologic | 1 | 1994 | 993 | 0.080 |
Why?
|
Kidney Function Tests | 1 | 2010 | 684 | 0.070 |
Why?
|
United States | 6 | 2024 | 72909 | 0.070 |
Why?
|
Shock | 1 | 2010 | 316 | 0.070 |
Why?
|
Prospective Studies | 9 | 2022 | 54807 | 0.070 |
Why?
|
Neutrophils | 1 | 2020 | 3769 | 0.070 |
Why?
|
Influenza, Human | 1 | 2019 | 1539 | 0.070 |
Why?
|
Myocardium | 2 | 2017 | 4764 | 0.070 |
Why?
|
Sarcoma | 1 | 2019 | 1799 | 0.070 |
Why?
|
Skull Fractures | 1 | 2009 | 202 | 0.070 |
Why?
|
Forecasting | 1 | 2016 | 2936 | 0.070 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2023 | 3637 | 0.070 |
Why?
|
ROC Curve | 2 | 2020 | 3612 | 0.070 |
Why?
|
Neoplasm Staging | 2 | 2019 | 11196 | 0.070 |
Why?
|
Cytoskeletal Proteins | 1 | 1992 | 1322 | 0.070 |
Why?
|
Pandemics | 3 | 2022 | 8721 | 0.070 |
Why?
|
Anticoagulants | 1 | 2022 | 4856 | 0.070 |
Why?
|
Fluorobenzenes | 1 | 2008 | 179 | 0.070 |
Why?
|
Hypopituitarism | 1 | 2009 | 253 | 0.070 |
Why?
|
Ventricular Function, Right | 1 | 2011 | 629 | 0.070 |
Why?
|
Disease Progression | 4 | 2015 | 13614 | 0.070 |
Why?
|
Physician-Patient Relations | 1 | 2020 | 3270 | 0.070 |
Why?
|
Protozoan Proteins | 1 | 1992 | 842 | 0.070 |
Why?
|
Heart Ventricles | 1 | 2019 | 3833 | 0.070 |
Why?
|
Receptor, Endothelin A | 2 | 2003 | 55 | 0.070 |
Why?
|
Young Adult | 4 | 2023 | 59857 | 0.070 |
Why?
|
Attitude of Health Personnel | 1 | 2020 | 3928 | 0.060 |
Why?
|
Ultrasonography | 3 | 2009 | 5987 | 0.060 |
Why?
|
NG-Nitroarginine Methyl Ester | 1 | 2006 | 261 | 0.060 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2008 | 391 | 0.060 |
Why?
|
Communication | 1 | 2020 | 3908 | 0.060 |
Why?
|
Abdominal Pain | 1 | 2012 | 1069 | 0.060 |
Why?
|
Nitroglycerin | 1 | 2006 | 331 | 0.060 |
Why?
|
Phenylephrine | 1 | 2006 | 291 | 0.060 |
Why?
|
Troponin T | 2 | 2022 | 785 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2020 | 4055 | 0.060 |
Why?
|
Obesity | 2 | 2024 | 13082 | 0.060 |
Why?
|
Cardiac Output, Low | 1 | 2006 | 192 | 0.060 |
Why?
|
Hyperemia | 1 | 2006 | 223 | 0.060 |
Why?
|
Risk Assessment | 6 | 2024 | 24275 | 0.060 |
Why?
|
Quality of Life | 4 | 2020 | 13463 | 0.060 |
Why?
|
Drug Resistance | 1 | 2010 | 1588 | 0.060 |
Why?
|
Placebos | 1 | 2008 | 1659 | 0.060 |
Why?
|
Diagnostic Imaging | 2 | 2016 | 3530 | 0.060 |
Why?
|
Quality of Health Care | 1 | 1999 | 4305 | 0.060 |
Why?
|
Peptides, Cyclic | 2 | 2003 | 390 | 0.060 |
Why?
|
Death, Sudden, Cardiac | 2 | 2009 | 1568 | 0.060 |
Why?
|
Sodium Chloride | 1 | 2006 | 578 | 0.060 |
Why?
|
Ventricular Dysfunction, Right | 1 | 2009 | 645 | 0.060 |
Why?
|
Prevalence | 2 | 2019 | 15828 | 0.050 |
Why?
|
Case Management | 1 | 2005 | 276 | 0.050 |
Why?
|
Sodium-Glucose Transporter 2 | 1 | 2023 | 89 | 0.050 |
Why?
|
Vascular Resistance | 2 | 2003 | 939 | 0.050 |
Why?
|
Nitric Oxide Synthase | 1 | 2006 | 911 | 0.050 |
Why?
|
Mitoxantrone | 1 | 2023 | 148 | 0.050 |
Why?
|
Immunotherapy | 2 | 2021 | 4746 | 0.050 |
Why?
|
Biopsy | 3 | 2021 | 6766 | 0.050 |
Why?
|
Sodium Chloride, Dietary | 1 | 2005 | 303 | 0.050 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2009 | 844 | 0.050 |
Why?
|
Venous Thromboembolism | 1 | 2016 | 1883 | 0.050 |
Why?
|
Renal Circulation | 1 | 2003 | 288 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3109 | 0.050 |
Why?
|
Boston | 2 | 2014 | 9334 | 0.050 |
Why?
|
Vasoconstrictor Agents | 1 | 2006 | 653 | 0.050 |
Why?
|
Endothelins | 1 | 2002 | 127 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3231 | 0.050 |
Why?
|
Patient Education as Topic | 2 | 2009 | 2331 | 0.050 |
Why?
|
Behavioral Risk Factor Surveillance System | 1 | 2023 | 212 | 0.050 |
Why?
|
Sulfonamides | 2 | 2008 | 1979 | 0.050 |
Why?
|
Ambulatory Care Facilities | 1 | 2008 | 937 | 0.050 |
Why?
|
Massachusetts | 1 | 2015 | 8882 | 0.050 |
Why?
|
Vasomotor System | 1 | 2002 | 208 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2013 | 3498 | 0.050 |
Why?
|
Exercise | 1 | 2018 | 5936 | 0.050 |
Why?
|
Prealbumin | 1 | 2023 | 264 | 0.040 |
Why?
|
Malignant Carcinoid Syndrome | 1 | 2000 | 31 | 0.040 |
Why?
|
Forearm | 1 | 2003 | 426 | 0.040 |
Why?
|
Ritonavir | 1 | 2022 | 331 | 0.040 |
Why?
|
Myocardial Contraction | 1 | 2006 | 1516 | 0.040 |
Why?
|
Practice Guidelines as Topic | 4 | 2024 | 7423 | 0.040 |
Why?
|
Cohort Studies | 7 | 2021 | 41680 | 0.040 |
Why?
|
Endocardium | 1 | 2021 | 249 | 0.040 |
Why?
|
Insulin Resistance | 1 | 2014 | 3988 | 0.040 |
Why?
|
Cholesterol | 1 | 2008 | 2902 | 0.040 |
Why?
|
Pulmonary Circulation | 1 | 2002 | 744 | 0.040 |
Why?
|
T-Lymphocytes | 1 | 2017 | 10256 | 0.040 |
Why?
|
Aspirin | 2 | 2023 | 3135 | 0.040 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2023 | 772 | 0.040 |
Why?
|
Syndrome | 1 | 2005 | 3271 | 0.040 |
Why?
|
Blood Urea Nitrogen | 2 | 2012 | 189 | 0.040 |
Why?
|
Waiting Lists | 1 | 2004 | 779 | 0.040 |
Why?
|
Arteriosclerosis | 1 | 2003 | 1055 | 0.040 |
Why?
|
Cytokines | 1 | 1994 | 7417 | 0.040 |
Why?
|
Antihypertensive Agents | 1 | 2008 | 2028 | 0.040 |
Why?
|
Cardiac Imaging Techniques | 1 | 2021 | 280 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2021 | 11090 | 0.040 |
Why?
|
Carcinoma, Ductal | 1 | 2019 | 97 | 0.040 |
Why?
|
Graft Rejection | 2 | 2023 | 4503 | 0.040 |
Why?
|
Drug Interactions | 1 | 2022 | 1416 | 0.040 |
Why?
|
Radioimmunoassay | 1 | 1998 | 860 | 0.040 |
Why?
|
Diagnosis, Differential | 3 | 2021 | 12973 | 0.040 |
Why?
|
Publication Bias | 1 | 1998 | 157 | 0.030 |
Why?
|
Myocardial Revascularization | 1 | 2021 | 795 | 0.030 |
Why?
|
Radiography | 1 | 2008 | 6941 | 0.030 |
Why?
|
Angina Pectoris | 1 | 2021 | 957 | 0.030 |
Why?
|
Azathioprine | 1 | 1998 | 354 | 0.030 |
Why?
|
C-Reactive Protein | 1 | 2008 | 3851 | 0.030 |
Why?
|
Child | 3 | 2023 | 80568 | 0.030 |
Why?
|
Troponin I | 1 | 2021 | 656 | 0.030 |
Why?
|
Age Factors | 4 | 2018 | 18382 | 0.030 |
Why?
|
Methylprednisolone | 1 | 2018 | 386 | 0.030 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2000 | 340 | 0.030 |
Why?
|
Death | 1 | 2021 | 686 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 2 | 2021 | 36547 | 0.030 |
Why?
|
Pleural Neoplasms | 1 | 2000 | 583 | 0.030 |
Why?
|
Coronary Circulation | 1 | 2021 | 1601 | 0.030 |
Why?
|
Lipids | 1 | 2006 | 3317 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 2006 | 3716 | 0.030 |
Why?
|
Blood Coagulation | 1 | 2021 | 1171 | 0.030 |
Why?
|
Gadolinium | 1 | 2020 | 966 | 0.030 |
Why?
|
Kidney Diseases | 2 | 2005 | 2100 | 0.030 |
Why?
|
Models, Cardiovascular | 1 | 2020 | 979 | 0.030 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2016 | 869 | 0.030 |
Why?
|
Blood Pressure | 3 | 2009 | 8530 | 0.030 |
Why?
|
Postoperative Complications | 2 | 2017 | 15802 | 0.030 |
Why?
|
Cost-Benefit Analysis | 2 | 2020 | 5531 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1787 | 0.030 |
Why?
|
Water-Electrolyte Imbalance | 2 | 2005 | 110 | 0.030 |
Why?
|
Androgens | 1 | 2021 | 1278 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2020 | 2863 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 2008 | 12529 | 0.030 |
Why?
|
Survival Analysis | 3 | 2018 | 10086 | 0.030 |
Why?
|
Drug Therapy, Combination | 2 | 2005 | 6306 | 0.030 |
Why?
|
Hypoglycemia | 1 | 2000 | 896 | 0.030 |
Why?
|
Telephone | 2 | 2008 | 627 | 0.030 |
Why?
|
Prostate | 1 | 2021 | 1758 | 0.030 |
Why?
|
RNA, Protozoan | 1 | 1992 | 46 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2023 | 9373 | 0.030 |
Why?
|
Magnetic Resonance Imaging, Cine | 1 | 2020 | 1093 | 0.030 |
Why?
|
Hepatomegaly | 1 | 2012 | 83 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2017 | 1835 | 0.020 |
Why?
|
Adolescent | 4 | 2023 | 88811 | 0.020 |
Why?
|
Signal Transduction | 2 | 2021 | 23597 | 0.020 |
Why?
|
Androgen Antagonists | 1 | 2021 | 1411 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4851 | 0.020 |
Why?
|
Critical Pathways | 1 | 2016 | 475 | 0.020 |
Why?
|
DNA, Protozoan | 1 | 1992 | 226 | 0.020 |
Why?
|
Lactates | 1 | 1993 | 398 | 0.020 |
Why?
|
Patient Selection | 1 | 2004 | 4248 | 0.020 |
Why?
|
Hyperglycemia | 1 | 2000 | 1389 | 0.020 |
Why?
|
Hypoglycemic Agents | 1 | 2024 | 3106 | 0.020 |
Why?
|
Bacterial Vaccines | 1 | 1994 | 400 | 0.020 |
Why?
|
Polyglycolic Acid | 1 | 1993 | 406 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2016 | 1777 | 0.020 |
Why?
|
Jugular Veins | 1 | 2012 | 211 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2021 | 2234 | 0.020 |
Why?
|
Glucose | 1 | 2022 | 4335 | 0.020 |
Why?
|
Mastectomy | 1 | 2019 | 1848 | 0.020 |
Why?
|
Ascites | 1 | 2012 | 336 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2020 | 6838 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2020 | 3678 | 0.020 |
Why?
|
Medical Oncology | 1 | 2022 | 2339 | 0.020 |
Why?
|
Data Collection | 1 | 1999 | 3318 | 0.020 |
Why?
|
Echocardiography, Doppler, Pulsed | 1 | 2009 | 68 | 0.020 |
Why?
|
Receptor, erbB-2 | 1 | 2020 | 2592 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2003 | 12059 | 0.020 |
Why?
|
Drug Synergism | 1 | 1994 | 1751 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2005 | 8037 | 0.020 |
Why?
|
Quality Indicators, Health Care | 1 | 1999 | 1804 | 0.020 |
Why?
|
Hospital Mortality | 2 | 2006 | 5339 | 0.020 |
Why?
|
Heart Function Tests | 1 | 2009 | 317 | 0.020 |
Why?
|
Cartilage | 1 | 1993 | 797 | 0.020 |
Why?
|
Thrombolytic Therapy | 1 | 1998 | 2050 | 0.020 |
Why?
|
British Columbia | 1 | 2009 | 238 | 0.020 |
Why?
|
Calcium | 1 | 2022 | 5769 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2018 | 2155 | 0.020 |
Why?
|
Terminology as Topic | 1 | 2016 | 1536 | 0.020 |
Why?
|
Viral Vaccines | 1 | 1994 | 596 | 0.020 |
Why?
|
Fibrinolytic Agents | 1 | 1998 | 2076 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 10727 | 0.020 |
Why?
|
Bumetanide | 1 | 2008 | 101 | 0.020 |
Why?
|
Mortality | 1 | 2019 | 2910 | 0.020 |
Why?
|
Patient Care Planning | 1 | 2013 | 903 | 0.020 |
Why?
|
Lactic Acid | 1 | 1993 | 1137 | 0.020 |
Why?
|
Furosemide | 1 | 2008 | 174 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2020 | 3615 | 0.020 |
Why?
|
Palliative Care | 1 | 2022 | 3640 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2014 | 1740 | 0.020 |
Why?
|
Thrombosis | 1 | 2021 | 2955 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2012 | 1729 | 0.020 |
Why?
|
Creatine Kinase | 1 | 2009 | 682 | 0.020 |
Why?
|
Contrast Media | 1 | 2020 | 5330 | 0.020 |
Why?
|
Reoperation | 1 | 2017 | 4308 | 0.020 |
Why?
|
Vaccination | 1 | 2019 | 3430 | 0.020 |
Why?
|
Smoking | 1 | 2003 | 9082 | 0.020 |
Why?
|
Cost of Illness | 1 | 2016 | 1949 | 0.020 |
Why?
|
Prostheses and Implants | 1 | 1993 | 1273 | 0.020 |
Why?
|
Polymers | 1 | 1993 | 1622 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2021 | 6542 | 0.020 |
Why?
|
Logistic Models | 1 | 1999 | 13273 | 0.010 |
Why?
|
Probability | 1 | 2009 | 2474 | 0.010 |
Why?
|
Preoperative Care | 1 | 2013 | 2248 | 0.010 |
Why?
|
Sex Factors | 1 | 1998 | 10611 | 0.010 |
Why?
|
Chronic Disease | 2 | 2011 | 9351 | 0.010 |
Why?
|
Benzothiadiazines | 1 | 2003 | 31 | 0.010 |
Why?
|
Shock, Cardiogenic | 1 | 2009 | 705 | 0.010 |
Why?
|
Hyponatremia | 1 | 2006 | 278 | 0.010 |
Why?
|
Sodium Chloride Symporter Inhibitors | 1 | 2003 | 77 | 0.010 |
Why?
|
Health Status Indicators | 1 | 2008 | 967 | 0.010 |
Why?
|
Life Expectancy | 1 | 2009 | 1247 | 0.010 |
Why?
|
Receptors, Endothelin | 1 | 2002 | 56 | 0.010 |
Why?
|
Lung | 1 | 2021 | 10046 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2014 | 3560 | 0.010 |
Why?
|
Workload | 1 | 2008 | 848 | 0.010 |
Why?
|
Base Sequence | 1 | 1992 | 12405 | 0.010 |
Why?
|
Patient Discharge | 1 | 2015 | 3460 | 0.010 |
Why?
|
Melanoma | 1 | 2020 | 5695 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 1992 | 13398 | 0.010 |
Why?
|
Systole | 1 | 2003 | 935 | 0.010 |
Why?
|
Office Visits | 1 | 2005 | 594 | 0.010 |
Why?
|
Indium Radioisotopes | 1 | 2000 | 113 | 0.010 |
Why?
|
Self Care | 1 | 2006 | 800 | 0.010 |
Why?
|
Health Services Research | 1 | 2008 | 1811 | 0.010 |
Why?
|
Hormone Antagonists | 1 | 2000 | 108 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 11858 | 0.010 |
Why?
|
Eligibility Determination | 1 | 2004 | 422 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 1992 | 17596 | 0.010 |
Why?
|
Cholesterol, LDL | 1 | 2008 | 2395 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2020 | 26282 | 0.010 |
Why?
|
Animals | 4 | 2016 | 168735 | 0.010 |
Why?
|
Potassium | 1 | 2003 | 1312 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2014 | 14643 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 1992 | 7599 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2009 | 6503 | 0.010 |
Why?
|
Somatostatin | 1 | 2000 | 459 | 0.010 |
Why?
|
Glucagon | 1 | 2000 | 533 | 0.010 |
Why?
|
Outpatients | 1 | 2006 | 1595 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2009 | 8522 | 0.010 |
Why?
|
Pilot Projects | 1 | 2011 | 8724 | 0.010 |
Why?
|
RNA, Messenger | 1 | 1992 | 12768 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2009 | 3477 | 0.010 |
Why?
|
Reference Values | 1 | 2002 | 4909 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2012 | 10380 | 0.010 |
Why?
|
Biodegradation, Environmental | 1 | 1993 | 220 | 0.010 |
Why?
|
Ribs | 1 | 1993 | 254 | 0.010 |
Why?
|
Polyesters | 1 | 1993 | 373 | 0.010 |
Why?
|
Decision Making | 1 | 2004 | 3955 | 0.010 |
Why?
|
Recurrence | 1 | 2002 | 8492 | 0.010 |
Why?
|
Mice | 2 | 1994 | 81782 | 0.010 |
Why?
|
Cattle | 1 | 1993 | 3801 | 0.000 |
Why?
|
Mice, Nude | 1 | 1993 | 3608 | 0.000 |
Why?
|
Insulin | 1 | 2000 | 6603 | 0.000 |
Why?
|
Blood Glucose | 1 | 2000 | 6422 | 0.000 |
Why?
|
Cartilage, Articular | 1 | 1993 | 1088 | 0.000 |
Why?
|
Extracellular Matrix | 1 | 1993 | 1727 | 0.000 |
Why?
|
Transplantation, Heterologous | 1 | 1993 | 2390 | 0.000 |
Why?
|
Feasibility Studies | 1 | 1993 | 5300 | 0.000 |
Why?
|
Cells, Cultured | 1 | 1993 | 18962 | 0.000 |
Why?
|
Tomography, X-Ray Computed | 1 | 2000 | 20690 | 0.000 |
Why?
|